Search research articles
Contact Us
Filters
Showing results (331-340 of 1,623) with videos related to
Page
of 163
Sort By:
Oncology
|
January 25, 2012
The promise and perils of measuring circulating tumor cells
Maurie Markman
Cancer Management and Research
|
July 28, 2011
Pegylated liposomal doxorubicin: appraisal of its current role in the management of epithelial ovarian cancer
Maurie Markman
Nature Reviews. Clinical Oncology
|
December 21, 2011
Ovarian cancer in 2011: Mutations and non-inferiority analyses show a way forward
Maurie Markman
Gynecologic Oncology
|
May 31, 2011
Docetaxel plus trabectedin appears active in recurrent or persistent ovarian and primary peritoneal cancer after up to three prior regimes: a phase II study of the Gynecologic Oncology Group
Maurie Markman
Journal of Cancer Research and Clinical Oncology
|
January 1, 1993
Phase 1 trials of intensive antineoplastic therapy: a need for a critical reassessment of who should be treated
M Markman
Journal of Cancer Research and Clinical Oncology
|
January 1, 1993
Cost: the new factor clinical cancer investigators must learn to consider
M Markman
Cleveland Clinic Journal of Medicine
|
October 31, 1998
Why should cancer patients participate in clinical trials?
M Markman
The Psychoanalytic Quarterly
|
April 1, 1997
Play in the treatment of adolescents
H Markman
Oncology
|
December 19, 2007
Use of systemic antineoplastic drug therapy after regulatory agency approval
Maurie Markman
Cleveland Clinic Journal of Medicine
|
February 2, 1999
Diagnosis and management of superior vena cava syndrome
M Markman
Page
of 163
Search research articles
Search
Showing results (331-340 of 1,623) with videos related to
Sort By:
Page
of 163
Oncology
|
January 25, 2012
The promise and perils of measuring circulating tumor cells
Maurie Markman
Cancer Management and Research
|
July 28, 2011
Pegylated liposomal doxorubicin: appraisal of its current role in the management of epithelial ovarian cancer
Maurie Markman
Nature Reviews. Clinical Oncology
|
December 21, 2011
Ovarian cancer in 2011: Mutations and non-inferiority analyses show a way forward
Maurie Markman
Gynecologic Oncology
|
May 31, 2011
Docetaxel plus trabectedin appears active in recurrent or persistent ovarian and primary peritoneal cancer after up to three prior regimes: a phase II study of the Gynecologic Oncology Group
Maurie Markman
Journal of Cancer Research and Clinical Oncology
|
January 1, 1993
Phase 1 trials of intensive antineoplastic therapy: a need for a critical reassessment of who should be treated
M Markman
Journal of Cancer Research and Clinical Oncology
|
January 1, 1993
Cost: the new factor clinical cancer investigators must learn to consider
M Markman
Cleveland Clinic Journal of Medicine
|
October 31, 1998
Why should cancer patients participate in clinical trials?
M Markman
The Psychoanalytic Quarterly
|
April 1, 1997
Play in the treatment of adolescents
H Markman
Oncology
|
December 19, 2007
Use of systemic antineoplastic drug therapy after regulatory agency approval
Maurie Markman
Cleveland Clinic Journal of Medicine
|
February 2, 1999
Diagnosis and management of superior vena cava syndrome
M Markman
Page
of 163